2023 PROGRAM
The event was held at the James L. Knight Center located downtown Miami, FL at 400 SE 2nd Ave.Â
7:30 AM
8:15 AM
8:25 AM
8:30 AM
8:30 AM
8:35 AM
8:50 AM
9:05 AM
9:20 AM
9:35 AM
10:00 AM
10:30 AM
11:15 AM
11:15 AM
11:20 AM
11:35 AM
11:50 AM
12:05 PM
12:20 PM
12:35 PM
1:00 PM
2:00 PM
2:30 PM
2:45 PM
2:45 PM
2:50 PM
3:05 PM
3:20 PM
3:35 PM
3:50 PM
4:15 PM
5:00 PM
5:00 PM
5:05 PM
5:20 PM
5:35 PM
5:50 PM
6:05 PM
6:30 PM
9:00 PM
WEDNESDAY, JANUARY 11
Check-in and Breakfast
Welcome Notes; Introductions
Announcement: Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET): Defining the future of Alzheimer's treatment, imaging and care
SESSION I: TRACER DEVELOPMENT AND EVALUATION
Introduction
Advances towards the identification of an α-synuclein Positron Emission Tomography radioligand for the diagnosis of Parkinson’s disease
Discovery of [18F]ACI-12589, a novel and promising PET-tracer for a-synuclein
Discovery and preclinical evaluation of two novel PET tracers for imaging non-AD tauopathies
In vivo head-to-head comparison of [18F]GTP1, [18F]PI2620, and [18F]MK6240 in Alzheimer’s disease
DIDACTIC PRESENTATION: ANTIBODY PET
Session I Discussion
P1 - POSTER SESSION/BREAK
SESSION II: TECHNICAL ADVANCES FOR CLINICAL APPLICATIONS
Introduction
Minimizing sample sizes for trials using MK-6240 outcomes: impact of processing method and choice of reference and target tissues
Inferring full ATN status from tau-PET using deep learning
Longitudinal modelling of tau transport and production dynamics in the human brain
Connectivity- versus gradient-based approaches to predict regional tau-PET across Alzheimer’s disease variants
Measuring tau in the basal forebrain: a comparison of MK6240 and flortaucipir
Session II Discussion
LUNCH
KEYNOTE: SYNAPTIC PATHOLOGY IN NEURODEGENERATION
Keynote Discussion
SESSION III: THRESHOLDS, VISUAL READS AND REAL WORLD IMAGING
Introduction
Biostatistical estimation of tau threshold hallmarks (BETTH) for tau imaging studies
Visual read of [18F]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with amyloid positivity and retrospective cognitive decline in an AD risk-enriched cohort
Head-to-head comparison of tau and amyloid PET visual reads for differential diagnosis: An international, multi-center study
Quantitative analysis of 8,895 real-world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study
Session III Discussion
P2: POSTER SESSION/BREAK
SESSION IV: NON-AD AND CO-PATHOLOGIES
Introduction
Tau burden evaluation by [18F] Flortaucipir PET and quantitative tau neuropathology in Alzheimer's disease and non-Alzheimer’s tauopathies
Pathologic correlations of [18F]-Flortaucipir imaging in non-Alzheimer corticobasal syndrome
Unveiling the neurobiological basis of F18-flortaucipir in different tauopathies using voxel-to-voxel histology to PET comparisons: the role of p-tau, iron and MAOB
Association of FDG-PET with co-pathologies in autopsy-proven AD
Session IV Discussion
RECEPTION
DAY 1 ENDS
WEDNESDAY, JANUARY 11
Check-in and Breakfast
Keith Johnson, MD, Massachusetts General Hospital
Maria Carrillo, PhD, Alzheimer's Association
CHAIRS: Julie Price, PhD, Massachusetts General Hospital
Chet Mathis, PhD, University of Pittsburgh
Chet Mathis, PhD, University of Pittsburgh
Chairs
Idriss Bennacef, PhD, Merck & Co.
Francesca Capotosti, PhD, AC Immune
Marc Skaddan, PhD, AbbVie
Matteo Tonietto, PhD, F. Hoffman-La Roche
Dag Sehlin, PhD, Uppsala University
Session I Discussion
P1 - POSTER SESSION/BREAK
CHAIRS: Suzanne Baker, PhD, Lawrence Berkeley National Laboratory
Bradley Christian, PhD, University of Wisconsin, Madison
Bradley Christian, PhD, University of Wisconsin, Madison
Chairs
J. Alex Becker, PhD, Massachusetts General Hospital
Nicolai Franzmeier, PhD, LMU Munich
Pavan Chaggar, PhD, University of Oxford
Nick Corriveau-Lecavalier, PhD, Mayo Clinic, Rochester
Theresa Harrison, PhD, University of California, Berkeley
Session II Discussion
LUNCH
Thomas Montine, MD, Stanford University
Keynote Discussion
CHAIRS: Pedro Rosa-Neto, MD, PhD, McGill University
Ansel Hillmer, PhD, Yale School of Medicine
Ansel Hillmer, PhD, Yale School of Medicine
Chairs
Alexandra Gogola, PhD, University of Pittsburgh School of Medicine
Sterling Johnson, PhD, University of Wisconsin School of Medicine and Public Health
David Soleimani-Meigooni, PhD, University of California, San Francisco
Ehud Zeltzer, MD, University of California, San Francisco
Session III Discussion
P2: POSTER SESSION/BREAK
CHAIRS: Milos Ikonomovic, MD, University of Pittsburgh
Melissa Murray, PhD, Mayo Clinic, Jacksonville
Melissa Murray, PhD, Mayo Clinic, Jacksonville
Chairs
Rodolfo Gatto, PhD, Mayo Clinic, Rochester
Cinthya Aguero, MD, MassGeneral Institute for Neurodegenerative Disease
Yuheng Chen, PhD, University of California, San Francisco
Marianne Chapleau, PhD, University of California, San Francisco
Session IV Discussion
RECEPTION
DAY 1 ENDS
7:30 AM
8:30 AM
8:30 AM
8:35 AM
8:50 AM
9:05 AM
9:20 AM
9:35 AM
10:00 AM
10:45 AM
10:45 AM
10:50 AM
11:05 AM
11:20 AM
11:35 AM
11:50 AM
12:15 PM
1:15 PM
1:15 PM
1:20 PM
1:35 PM
1:50 PM
2:05 PM
2:20 PM
2:35 PM
3:00 PM
3:30 PM
3:45 PM
4:30 PM
4:30 PM
4:35 PM
4:50 PM
5:05 PM
5:20 PM
5:45 PM
8:00 PM
THURSDAY, JANUARY 12
Breakfast
SESSION V: AD NEUROPATHOLOGY
Introduction
Specific associations between plasma biomarkers and post-mortem amyloid plaque and neurofibrillary tau tangle loads
Intersection of amyloid-β and tau brain pathology influences plasma phosphorylated tau levels
Tangle maturity markers associate with tau PET and cognitive measures in hippocampus
Postmortem validation of 18F-MK-6240 PET using autoradiography and in-vitro binding combined with antibody-based assays in frozen brains from two autopsy cases
Session V Discussion
P3: POSTER SESSION/BREAK
SESSION VI: HETEROGENEITY IN THE AD CASCADE
Introduction
Longitudinal increases in tau emerge alongside early amyloid change in Down syndrome
Cross-sectional and longitudinal associations between amyloid- and tau-PET in early-onset Alzheimer’s Disease: update from the LEADS study
Amyloid PET Burden Predicts Longitudinal Cognitive Trajectories in a Heterogeneous ADRD Cohort
Variations in gamma-secretase function across PSEN1 pathogenic variants strongly predict the clinical, cognitive, and biomarker progression of autosomal dominant Alzheimer’s disease (MGH, DIAN)
Session VI Discussion
LUNCH
SESSION VII: TAU PET AND MRI: MULTIMODALITY INSIGHTS
Introduction
Mapping tau accumulation to the functional and structural organization of the brain in Alzheimer’s disease
Baseline tau PET shows stronger associations with cognitive and behavioral changes over time than cortical thickness
A Central Role of Locus Coeruleus in the Initial Spatiotemporal Progression of Tau and its Contribution to Cognition
Tau Propagation in the Brain Olfactory Circuits Contributes to Smell Perception Changes in Aging
Medial temporal lobe subregional microstructure measured with ultra-high resolution diffusion imaging as a biomarker for early tau pathology and memory impairment (UCI)
Session VII Discussion
KEYNOTE: On making neuroimaging studies more equitable, inclusive, and relevant
Keynote Discussion
P4: POSTER SESSION/BREAK
SESSION VIII: LIFESTYLE AND LIVED EXPERIENCES
Introduction
African American racialization modifies the association between apolipoprotein-E4 and amyloid deposition
Cardiovascular risk and AD biomarkers in unimpaired older adults: A comparison of U.S. POINTER and ADNI
Association between mid-life social factors and estimated late life amyloid burden: the Atherosclerosis Risk in Communities (ARIC)-PET study
Session VIII Discussion
RECEPTION
DAY 2 ENDS
THURSDAY, JANUARY 12
Breakfast
CHAIRS: Teresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Laetitia Lemoine, PhD, Karolinska Institutet
Laetitia Lemoine, PhD, Karolinska Institutet
Chairs
Gemma Salvado, PhD, Lund University
Melissa Murray, PhD, Mayo Clinic, Jacksonville
Christina Moloney, PhD, Mayo Clinic, Jacksonville
Tobey Betthauser, PhD, University of Wisconsin-Madison
Session V Discussion
P3: POSTER SESSION/BREAK
CHAIRS: Heidi Jacobs, PhD, Massachusetts General Hospital
Susan Landau, PhD, University of California, Berkeley
Susan Landau, PhD, University of California, Berkeley
Chairs
Matt Zammit, PhD, University of Wisconsin-Madison
Nidhi Mundada, PhD, University of California, San Francisco
Kyan Younes, PhD, Stanford University
Stephanie Schultz, PhD, Massachusetts General Hospital
Session VI Discussion
LUNCH
CHAIRS: Annie Cohen, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
Beth Mormino, PhD, Stanford University
Chairs
Julie Ottoy, PhD, University of Toronto
Ellen Singleton, PhD, Lund University
Elisenda Bueicheku, PhD, Massachusetts General Hospital/Harvard Medical School
Ibai Diez, PhD, Massachusetts General Hospital/Harvard Medical School
Jenna Adams, PhD, University of California, Irvine
Session VII Discussion
Monica Rivera Mindt, PhD, Fordham University
Keynote Discussion
P4: POSTER SESSION/BREAK
CHAIRS: Gil Rabinovici, MD, University of California, San Francisco
Tobey Betthauser, PhD, University of Wisconsin-Madison
Tobey Betthauser, PhD, University of Wisconsin-Madison
Chairs
Sarah Royse, PhD, University of Pittsburgh
Susan Landau, PhD, University of California, Berkeley
Renee Groechel, PhD, NINDS
Session VIII Discussion
RECEPTION
DAY 2 ENDS
7:30 AM
7:45 AM
9:00 AM
9:00 AM
9:05 AM
9:20 AM
9:35 AM
9:50 AM
10:05 AM
10:20 AM
10:45 AM
11:30 AM
11:30 AM
11:35 AM
11:50 AM
12:05 PM
12:20 PM
12:35 PM
12:50 PM
1:05 PM
2:05 PM
2:30 PM
3:00 PM
3:15 PM
4:00 PM
4:15 PM
4:15 PM
4:20 PM
4:35 PM
4:50 PM
5:05 PM
5:30 PM
5:35 PM
FRIDAY, JANUARY 13
Breakfast
NEW!Mentor Session
SESSION IX: LONGITUDINAL CHANGES IN TAU AND AMYLOID MARKERS
Introduction
Longitudinal tau accumulation is associated with faster memory decline in typical aging and preclinical Alzheimer’s disease
The use of plasma markers to predict tau accumulation in a stage-specific manner
Temporal dynamics of plasma pTau217 and amyloid PET in preclinical AD
Longitudinal changes in Alzheimer’s disease-related plasma biomarkers in relation to changes in PiB PET measures of brain amyloid
Longitudinal bidirectional associations between sleep and Alzheimer’s pathology in at-risk cognitively unimpaired older adults
Session IX Discussion
P5: POSTER SESSION/BREAK
SESSION X: FLUID BIOMARKERS IN AD
Introduction
Plasma p-tau217 ratios associated with amyloid and tau PET measures in preclinical AD: Findings from the AHEAD 3-45 Study screening data
Plasma biomarkers as stand-alone tests to rule out Alzheimer's disease
Comparative performance of three plasma Aβ42/Aβ40 and two plasma p-tau181 assays versus amyloid-PET imaging status
Prognostic utility of plasma p217+tau vs amyloid and tau PET in the Alzheimer continuum
Associations of blood biomarkers with early-onset Alzheimer’s disease pathology
Associations between amyloid PET, CSF pTau, and plasma biomarkers in memory clinic patients
LUNCH
Session X Discussion
KEYNOTE: BIOFLUIDS AND IMAGING: TWO SIDES OF THE SAME COIN
Keynote Discussion
P6: POSTER SESSION/BREAK
AWARDS
SESSION XI: PLASMA WITH OTHER MODALITIES
Introduction
Plasma biomarkers associated with cortical brain structure and multi-domain cognition in Alzheimer’s disease and Parkinson’s disease
Relationships of blood insulin with brain structures and plasma Aβ42 to Aβ40 ratio in a multi-ethnic cohort of older adults
Unique biological pathways associated with plasma ptau species and AD PET: an imaging-transcriptomic study
Session XI Discussion
CONCLUDING REMARKS
CONFERENCE ENDS
FRIDAY, JANUARY 13
Breakfast
NEW!Mentor Session
CHAIRS: Keith Johnson, MD Massachusetts General Hospital
William Jagust, MD, University of California, Berkeley
William Jagust, MD, University of California, Berkeley
Chairs
Corrina Fonseca, PhD, University of California, Berkeley
Cécile Tissot, PhD, McGill University
Karly Cody, PhD, University of Wisconsin-Madison
Murat Bilgel, PhD, NIA
Bery Mohammediyan, MSc, McGill University
Session IX Discussion
P5: POSTER SESSION/BREAK
CHAIRS: Henrik Zetterberg, MD, PhD, University of Gothenburg
Donna Wilcox, PhD, University of Kentucky College of Medicine
Donna Wilcox, PhD, University of Kentucky College of Medicine
Chairs
Reisa Sperling, MD, MGH/Harvard Medical School
Joseph Therriault, PhD, McGill University
Alicia Algeciras-Schimnich, PhD, Mayo Clinic, Rochester
Azadeh Feizpour, PhD, Austin Health
Paige Logan, PhD, Indiana University School of Medicine
Marina Bluma, PhD, Karolinska University
LUNCH
Session X Discussion
Thomas Karikari, PhD, University of Pittsburgh School of Medicine
Keynote Discussion
P6: POSTER SESSION/BREAK
AWARDS
CHAIR: Thomas Karikari, PhD, University of Pittsburgh
Suzanne Schindler, MD, PhD, Washington University
Suzanne Schindler, MD, PhD, Washington University
Chairs
Gillian Coughlan, PhD, Massachusetts General Hospital
Brandon Hall, MSc, University of Southern California
Min Su Kang, PhD, Sunnybrook Research Institute
Session XI Discussion
Teresa Gomez-Isla, MD, PhD, Massachusetts General Hospital
Thomas Karikari, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
Julie Price, PhD, Massachusetts General Hospital
Thomas Karikari, PhD, University of Pittsburgh
Beth Mormino, PhD, Stanford University
Julie Price, PhD, Massachusetts General Hospital
CONFERENCE ENDS